7 completed, 2 unknown, 1 terminated, 1 withdrawn. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Unknown 1 |
Follow lintuzumab: new trials by email Literature Review of lintuzumab trials Research Report on lintuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes lintuzumab, 5-azacytidine - Leukemia, Myelodysplastic Syndromes | Phase 2 | Terminated | Alison Walker | 7 | 2009-11-01 | 2017-05-10 |
| A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) lintuzumab, lenalidomide - Myelodysplastic Syndrome (MDS) | Phase 1 | Completed | Seagen Inc. | 13 | 2008-03-01 | 2011-10-12 |
| A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML Lintuzumab (SGN-33), Low dose cytarabine, Placebo - Acute Myeloid Leukemia | Phase 2 | Completed | Seagen Inc. | 211 | 2007-09-01 | 2015-01-07 |
| A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome lintuzumab - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Seagen Inc. | 82 | 2005-11-01 | 2014-12-18 |
| Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia lintuzumab - Leukemia | Phase 2 | Unknown | Jonsson Comprehensive Cancer Center | 2001-02-01 | 2013-12-19 | |
| Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia filgrastim, lintuzumab, arsenic trioxide - Leukemia | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 35 | 2000-11-01 | 2013-01-16 |
| Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia lintuzumab, cytarabine, etoposide - Leukemia | Phase 3 | Unknown | Facet Biotech | 2000-03-01 | 2013-11-06 | |
| Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome lintuzumab - Myelodysplastic Syndromes | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 1999-02-01 | 2012-07-11 | |
| Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia lintuzumab - Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 24 | 1996-10-01 | 2013-06-25 |
| Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome filgrastim, lintuzumab, cytarabine - Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 60 | 1996-07-01 | 2013-07-03 |
| Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission lintuzumab, cytarabine, idarubicin - Leukemia | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 40 | 1994-08-01 | 2013-06-24 |
Leukemia (9) · Myelodysplastic Syndromes (6) · Leukemia, Myeloid, Acute (5) · Anemia, Refractory, with Excess of Blasts (4) · Leukemia, Myelomonocytic, Chronic (4) · Hematologic Diseases (3) · Blast Crisis (2) · Leukemia, Erythroblastic, Acute (2) · Leukemia, Megakaryoblastic, Acute (2) · Leukemia, Monocytic, Acute (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myelomonocytic, Acute (2) · Leukemia, Promyelocytic, Acute (2) · Anemia, Refractory (1) · Myeloproliferative Disorders (1)
Memorial Sloan Kettering Cancer Center (4) · Seagen Inc. (3) · Alison Walker (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Facet Biotech (1) · Jonsson Comprehensive Cancer Center (1)
United States (10) · Belgium (2) · France (2) · Germany (2) · Netherlands (2) · United Kingdom (2) · Austria (1) · Canada (1) · Denmark (1) · Norway (1) · Switzerland (1)
Eric Sievers, MD (2) · Joseph G. Jurcic, MD (2) · Alison Walker, MD (1) · Christos E. Emmanouilides, MD (1) · Daniel Levitt, MD, PhD (1) · David A. Scheinberg, MD, PhD (1) · Eric Sievers, M.D. (1) · Heinz Zwierzina, MD (1) · Peter Maslak, MD (1)
P30CA016042 (1)